Tislelizumab in Addition to BACE in Patients with NSCLC

NCT05058560 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Tislelizumab

Sponsor

The First Affiliated Hospital of Zhengzhou University